Forward Ventures

Description

Forward Ventures, founded in 1993, has a team of investment professionals with extensive experience in venture capital and operations. Forward has invested in over 50 companies since it was founded in 1993 and currently has approximately $500 million in capital under management. The most recent fund, Forward V, continues Forward Ventures' program of life sciences and health care venture investing in companies of all stages. The firm is headquartered in a 40,000 square-foot research building that also serves as an incubator for its portfolio companies.

Forward Ventures, founded in 1993, is a leading life-science venture capital firm located in San Diego. Forward has a team of investment professionals with extensive experience in entrepreneurship, venture capital and operations. Our firm has invested in over 50 companies since it was founded in 1993 and currently has more than $500 million in capital under management. The most recent fund, Forward V, continues Forward Ventures’ program of life sciences and health care venture investing in companies of all stages of development.

Dr. Royston is a Founding Managing Partner of Forward Ventures. Dr. Royston has been involved in the biotechnology industry in San Diego from its inception in 1978 with the founding of Hybritech, Inc. (later acquired by Eli Lilly) and with the founding of Idec Pharmaceuticals in 1986 (which later merged with Biogen).

A 27-year veteran of venture capital investing, Mr. Fleming has helped raise and manage six venture funds totaling more than $500 million and has served on the boards of 19 venture-backed companies. He has extensive experience in all aspects of venture management and finance, including fund-raising, investor relations, operations and portfolio development. He has made investments, managed portfolio companies, raised funds, pursued business development, taken companies public and successfully exited investments through public-market sales and buyouts.

Previously he was Chairman, Chief Executive Officer and President of Aurora Biosciences Corporation (acquired by Vertex Pharmaceuticals for $600 million). Before Aurora, Dr. Collinson was Chief Executive Officer of privately held Andaris (acquired by Quadrant plc, now part of Elan Corporation plc). He held senior management positions at GlaxoWellcome plc (now GlaxoSmithKline plc) and Baxter International, and was a consultant with The Boston Consulting Group.

Fact sheet

Company contacts

Products & services

Similar companies nearby